Back to Search Start Over

Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis.

Authors :
Vaz-Luis, Ines
Vaz-Luis, Ines
Di Meglio, Antonio
Havas, Julie
El-Mouhebb, Mayssam
Lapidari, Pietro
Presti, Daniele
Soldato, Davide
Pistilli, Barbara
Dumas, Agnes
Menvielle, Gwenn
Charles, Cecile
Everhard, Sibille
Martin, Anne-Laure
Cottu, Paul H
Lerebours, Florence
Coutant, Charles
Dauchy, Sarah
Delaloge, Suzette
Lin, Nancy U
Ganz, Patricia A
Partridge, Ann H
André, Fabrice
Michiels, Stefan
Vaz-Luis, Ines
Vaz-Luis, Ines
Di Meglio, Antonio
Havas, Julie
El-Mouhebb, Mayssam
Lapidari, Pietro
Presti, Daniele
Soldato, Davide
Pistilli, Barbara
Dumas, Agnes
Menvielle, Gwenn
Charles, Cecile
Everhard, Sibille
Martin, Anne-Laure
Cottu, Paul H
Lerebours, Florence
Coutant, Charles
Dauchy, Sarah
Delaloge, Suzette
Lin, Nancy U
Ganz, Patricia A
Partridge, Ann H
André, Fabrice
Michiels, Stefan
Source :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology; vol 40, iss 19, 2148-2162; 0732-183X
Publication Year :
2022

Abstract

PurposeFatigue is recognized as one of the most burdensome and long-lasting adverse effects of cancer and cancer treatment. We aimed to characterize long-term fatigue trajectories among breast cancer survivors.MethodsWe performed a detailed longitudinal analysis of fatigue using a large ongoing national prospective clinical study (CANcer TOxicity, ClinicalTrials.gov identifier: NCT01993498) of patients with stage I-III breast cancer treated from 2012 to 2015. Fatigue was assessed at diagnosis and year 1, 2, and 4 postdiagnosis. Baseline clinical, sociodemographic, behavioral, tumor-related, and treatment-related characteristics were available. Trajectories of fatigue and risk factors of trajectory-group membership were identified by iterative estimates of group-based trajectory models.ResultsThree trajectory groups were identified for severe global fatigue (n = 4,173). Twenty-one percent of patients were in the high-risk group, having risk estimates of severe global fatigue of 94.8% (95% CI, 86.6 to 100.0) at diagnosis and 64.6% (95% CI, 59.2 to 70.1) at year 4; 19% of patients clustered in the deteriorating group with risk estimates of severe global fatigue of 13.8% (95% CI, 6.7 to 20.9) at diagnosis and 64.5% (95% CI, 57.3 to 71.8) at year 4; 60% were in the low-risk group with risk estimates of 3.6% (95% CI, 2.5 to 4.7) at diagnosis and 9.6% (95% CI, 7.5 to 11.7) at year 4. The distinct dimensions of fatigue clustered in different trajectory groups than those identified by severe global fatigue, being differentially affected by sociodemographic, clinical, and treatment-related factors.ConclusionOur findings highlight the multidimensional nature of cancer-related fatigue and the complexity of its risk factors. This study helps to identify patients with increased risk of severe fatigue and to inform personalized interventions to ameliorate this problem.

Details

Database :
OAIster
Journal :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology; vol 40, iss 19, 2148-2162; 0732-183X
Notes :
application/pdf, Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol 40, iss 19, 2148-2162 0732-183X
Publication Type :
Electronic Resource
Accession number :
edsoai.on1344354265
Document Type :
Electronic Resource